Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer

NCT02980809 is registered in ClinicalTrials.gov with First Hospitals affiliated to the China PLA General Hospital as lead sponsor.

NCT NCT02980809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02980809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
Lead sponsor
First Hospitals affiliated to the China PLA General Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2017
Completion date
March 31, 2020
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer